Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
Wave Life Sciences Ltd. (Nasdaq: WVE) will host a live webcast and conference call on Thursday, February 26, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and provide business updates. The event will be accessible via the "Investor Events" section of their website, with an archived version available afterward. Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines for various disorders.
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
Wave Life Sciences will host a live webcast and conference call on Thursday, February 26, 2026, at 8:30 a.m. ET to announce its fourth quarter and full year 2025 financial results. The event will also include business updates and will be accessible via their investor relations website.
Analysts Confirm Bullish Outlook on Wave Life (WVE) Over Obesity Treatment
Analysts are maintaining a bullish outlook on Wave Life Sciences (WVE) due to its obesity treatment, WVE-007, with BofA initiating coverage and projecting significant sales. Canaccord Genuity and H.C. Wainwright reiterated Buy ratings, raising price targets after Wave Life regained full rights to WVE-006 from GSK, which positions the company as a fully integrated commercial entity. While acknowledging WVE's potential, the article suggests specific AI stocks might offer greater upside and less downside risk.
Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program
Wave Life Sciences (WVE) is experiencing strong bullish sentiment from analysts, with all 15 analysts assigning Buy ratings and a projected median 1-year price target indicating over 154% upside. This optimism is partly due to GlaxoSmithKline transferring rights for WVE-006, an alpha-1 antitrypsin deficiency treatment, back to Wave Life Sciences. The company, which specializes in RNA medicines, also has other programs like WVE-007, which is considered a significant part of its valuation.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from Analysts
WAVE Life Sciences Ltd. (NASDAQ:WVE) has received a consensus "Moderate Buy" rating from fifteen analysts, with an average 12-month price target of $32.56, indicating a 157% upside from its current price of $12.68. Insider activity includes CFO Kyle Moran selling 3,588 shares and major shareholder GSK purchasing 1,470,000 shares, increasing its stake. The company is a clinical-stage genetic medicines firm focusing on stereopure oligonucleotide therapies for serious diseases.
Kyle Moran Sells 3,588 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock
WAVE Life Sciences CFO Kyle Moran sold 3,588 shares on February 9th for approximately $48,259, reducing his stake by 2.6%. This follows larger sales in December and comes as the company missed recent earnings and revenue expectations, experiencing negative margins. Despite this, analysts maintain a "Moderate Buy" consensus rating with a target price of $32.69.
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 1,883 Shares of Stock
Chris Francis, an insider at WAVE Life Sciences (NASDAQ:WVE), sold 1,883 shares of the company's stock on February 9th at an average price of $13.45, reducing his stake by 2.95%. This sale follows previous transactions in January and December. Despite recent analyst price target increases, WVE shares traded down 2.4% to $13.27, and the company reported a quarterly EPS miss and revenue shortfalls, indicating ongoing unprofitability.
WAVE Life Sciences (NASDAQ:WVE) Given New $27.00 Price Target at Wells Fargo & Company
Wells Fargo & Company has reiterated an "overweight" rating on WAVE Life Sciences (NASDAQ:WVE) but adjusted its price target down to $27.00 from $29.00. This new target suggests a potential upside of approximately 109.59% from the stock's current trading price. The company currently holds a "Moderate Buy" consensus rating from analysts, with a collective price target of $32.56.
Paul Bolno Sells 10,480 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock
WAVE Life Sciences CEO Paul Bolno sold 10,480 shares of company stock for $140,956 on February 9th, reducing his stake by 3.66%. The stock traded down approximately 2.4% to $13.27, with a market capitalization of $2.22 billion. Despite negative recent quarterly earnings, analysts maintain a "Moderate Buy" consensus and an average price target of $32.69.
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 3,228 Shares of Stock
Chandra Vargeese, an insider at WAVE Life Sciences (NASDAQ:WVE), sold 3,228 shares of the company's stock on February 9th at an average price of $13.45, reducing their stake by 0.78%. The sale totaled approximately $43,417. This transaction occurred as the company's stock traded down $0.32 to $13.27, with a market cap of $2.22 billion, and reported quarterly earnings per share below analyst expectations.
(02/11/26) Top Picks 2026: Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE) is recommended as a top biotech pick for 2026 due to its pioneering RNA chemistry platform, PRISM, and promising clinical data for WVE-007 in obesity treatment. The drug's "muscle sparing" effect differentiates it from GLP-1s, and its potential for once-or-twice-yearly dosing suggests significant market potential and M&A speculation. Upcoming data readouts for WVE-007 are anticipated to be major catalysts for the stock.
Assessing Wave Life Sciences (WVE) Valuation After A 7x Three Year Total Return
Wave Life Sciences (WVE) has seen a significant 7x total return over three years, prompting a closer look at its valuation. While a popular narrative suggests the stock is 59.3% undervalued with a fair value of $33.06 due to its RNA platform and pipeline, another perspective highlights an expensive P/S ratio of 22.5x compared to the industry average. Investors are encouraged to build their own narrative and consider both potential rewards and risk factors before making investment decisions.
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen has downgraded WAVE Life Sciences (NASDAQ:WVE) from a "hold" to a "sell" rating. Despite this, 14 other analysts maintain a "Buy" rating, with a consensus of "Moderate Buy" and an average target price of $32.69. The company recently missed quarterly EPS and revenue estimates, and shows negative margins, though major shareholder GSK purchased 1.47 million shares.
Will Regaining Full Rights to WVE-006 and Pursuing FDA Fast Track Change Wave Life Sciences' (WVE) Narrative
Wave Life Sciences (WVE) has reacquired full global rights to WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency, from GSK. This move allows Wave to retain all future economics for WVE-006 and accelerate its US regulatory plans, including discussions for potential FDA accelerated approval in 2026. The article suggests this could significantly reshape Wave's investment narrative by adding a new, company-defining catalyst, though it also increases the company's direct exposure to development and commercial risk.
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment
Wave Life Sciences (WVE) has regained full rights to WVE-006, a potential treatment for alpha-1 antitrypsin deficiency, from GSK. The company plans to accelerate its strategy for the drug, seeking an accelerated approval pathway with the FDA. Wedbush analyst Yun Zhong maintained a Buy rating on WVE stock with a $33 price target.
Wave Life Sciences receives back rights to AATD therapy from GSK
Wave Life Sciences has regained full global rights to its investigational alpha-1 antitrypsin deficiency (AATD) therapy, WVE-006, from GSK. This follows GSK's decision to discontinue its non-gene therapy rare disease research and development portfolio, which included WVE-006. Wave Life Sciences is now evaluating options for the continued development of the therapy.
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment
Wave Life Sciences (WVE) has reacquired full rights to WVE-006, a potential treatment for alpha-1 antitrypsin deficiency, a rare genetic disorder with no current approved therapies for its lung and liver manifestations. The company plans to accelerate its strategy for the drug, including pursuing an accelerated approval pathway with the FDA, and maintains a collaboration with GSK that includes potential milestones up to $2.8 billion. Wedbush analyst Yun Zhong has maintained a Buy rating on WVE with a $33 price target.
Assessing Wave Life Sciences (WVE) Valuation After Regaining Global Rights To WVE-006 From GSK
Wave Life Sciences (WVE) has regained full global rights to its RNA editing candidate WVE-006 from GSK and plans to pursue FDA accelerated approval. Despite a significant 90-day share price return of 69.16%, the company, with current revenue of $109.23M and a net loss of $121.946M, is still considered undervalued by a narrative fair value of $31.93 against its current price of $13.33. However, its high P/S ratio of 22.3x raises concerns about valuation risk, especially considering that the fair value relies on optimistic future growth and earnings multiples.
Assessing Wave Life Sciences (WVE) Valuation After Regaining Global Rights To WVE-006 From GSK
Wave Life Sciences (WVE) has regained global rights to its RNA editing candidate WVE-006 from GSK and plans to pursue FDA accelerated approval. Despite a significant share price return, the company still shows a net loss, and its share price is below the average analyst target, suggesting a potential buying opportunity. However, risks include potential trial disappointments and failure to meet partnership revenue expectations, while its P/S ratio appears high compared to the industry and peers.
Wave Life Sciences Ltd. (WVE): Analyst Consensus Highlights 143.73% Potential Upside for Biotech Innovator
Wave Life Sciences Ltd. (WVE) is a Singapore-based biotechnology company focusing on RNA medicine development through its PRISM platform. Despite financial challenges like negative P/E and EPS, analysts maintain an overwhelmingly positive outlook with 15 buy ratings and an average target price of $32.73, indicating a potential upside of 143.73%. The company's robust pipeline and strategic collaborations with GlaxoSmithKline, Takeda Pharmaceutical, and Asuragen contribute to this optimism.
Wave Life Sciences price target raised to $50 from $47 at Clear Street
Clear Street has increased its price target for Wave Life Sciences (WVE) to $50 from $47, maintaining a Buy rating. This adjustment follows GSK's return of rights for WVE-006, which Clear Street views as a positive development, despite the stock's muted reaction due to the greater emphasis on WVE-007 in Wave Life's valuation. The firm retains its belief in the WVE-006 program.
Wave Life Sciences stock rises after regaining full rights to AATD therapy
Wave Life Sciences (NASDAQ:WVE) saw its stock increase by 2.1% after reacquiring full rights to WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency (AATD). The company plans to accelerate its registrational strategy and seek accelerated FDA approval, with regulatory feedback expected by mid-2026. WVE-006 aims to be a first-in-class treatment for the root cause of AATD, a rare condition affecting lung and liver.
Wave Life Sciences (WVE) Reclaims Rights to AATD Asset WVE-006
Wave Life Sciences (WVE) has reacquired full rights to its AATD treatment candidate, WVE-006, from GSK, planning an accelerated approval process and anticipating discussions with the FDA by mid-year. The biotechnology company, focused on RNA medicines for rare and prevalent disorders, shows strong financial health despite profitability challenges. Analysts maintain a positive outlook, though potential concerns about financial result manipulation and the inherent risks of the biotech industry warrant monitoring.
Wave Life Sciences receives back rights to AATD therapy from GSK
Wave Life Sciences has regained full rights to its alpha-1 antitrypsin deficiency (AATD) therapy, WVE-006, from GSK. Wave indicated its intention to pursue an accelerated approval pathway for the asset. This decision follows an agreement between the two companies.
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences has regained full rights to WVE-006, an RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), from GSK, enabling them to accelerate its registrational strategy. The company plans to engage with the FDA for a potential accelerated approval pathway, with regulatory feedback expected mid-2026, and anticipates data from ongoing clinical trials in early and later 2026. WVE-006 aims to address both lung and liver manifestations of AATD, a rare condition affecting 200,000 individuals in the U.S. and Europe.
Wave RNA drug for rare lung and liver disease heads for FDA talks
Wave Life Sciences has regained full rights to its investigational RNA editing therapeutic, WVE-006, aimed at treating alpha-1 antitrypsin deficiency (AATD), and plans to accelerate its registrational strategy, including engagement with the FDA for a potential accelerated approval pathway. Regulatory feedback is anticipated by mid-2026, with additional clinical trial data expected throughout 2026. The company also reported an expanded collaboration with GSK and expects a cash runway extending into the third quarter of 2028.
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences has regained full rights to WVE-006, an RNA editing therapeutic candidate for alpha-1 antitrypsin deficiency (AATD), from GSK. The company plans to accelerate its registrational strategy and engage with the FDA for a potential accelerated approval pathway for WVE-006, which aims to address both lung and liver manifestations of AATD. Wave expects regulatory feedback by mid-2026 and continues to report progress on its RestorAATion-2 clinical trial and collaboration with GSK.
Wave Life Sciences Ltd Accelerates Regulatory Engagement for WVE-006
Wave Life Sciences Ltd is accelerating regulatory engagement for WVE-006, a treatment for AATD, after regaining full rights from GSK. The company plans to seek FDA accelerated approval and expects data from the RestorAATion-2 trial in Q1 2026 and later in the year. Wave's cash runway is projected to extend into the third quarter of 2028.
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences has regained full rights to WVE-006, an investigational RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), from GSK. The company plans to accelerate its registrational strategy and engage with the FDA for a potential accelerated approval pathway, with regulatory feedback expected mid-2026. Data from the RestorAATion-2 clinical trial's 400 mg multidose cohort are on track for Q1 2026, and 600 mg cohort data are expected later in 2026.
How Investors May Respond To Wave Life Sciences (WVE) Expanding PRISM RNA Platform Via Big-Pharma Partnerships
Wave Life Sciences' PRISM RNA platform and its partnerships with major pharmaceutical companies like GlaxoSmithKline and Takeda are central to its investment narrative, aiming to translate scientific promise into commercially viable drugs. Despite recent positive attention, investors should consider the company's ongoing losses, high valuation, and upcoming lock-up expiry, as well as divergent fair value estimates. The article emphasizes that while partnerships reinforce short-term catalysts, execution on cash burn control and strong data generation remain critical for sustained engagement and funding.
How Investors May Respond To Wave Life Sciences (WVE) Expanding PRISM RNA Platform Via Big-Pharma Partnerships
Wave Life Sciences' PRISM RNA platform is gaining attention through partnerships with major pharmaceutical companies like GlaxoSmithKline and Takeda. While these collaborations could expand research and share expertise, investors need to consider the company's ongoing losses, dilution, and high valuation. The success hinges on upcoming trial results and the ability to manage cash burn, with current market sentiment suggesting elevated expectations.
Federated Hermes Inc. Has $27.46 Million Position in WAVE Life Sciences Ltd. $WVE
Federated Hermes Inc. significantly increased its stake in WAVE Life Sciences Ltd. (NASDAQ:WVE) by 678,144.7% in Q3, now holding 3,750,693 shares valued at $27.46 million. This makes Federated Hermes Inc. one of several institutional investors boosting their positions, with institutional investors collectively owning nearly 90% of the company. Despite positive analyst ratings and an average price target of $31.67, the company faces challenges including an earnings per share miss in Q3 and significant insider selling.
Emerald Mutual Fund Advisers Trust Sells 171,427 Shares of WAVE Life Sciences Ltd. $WVE
Emerald Mutual Fund Advisers Trust reduced its stake in WAVE Life Sciences Ltd. by 8.8%, selling 171,427 shares, though it still holds over 1.7 million shares valued at about $12.93 million. This comes amidst other institutional investors adjusting their positions, and notable insider trading activity including a large purchase by GSK and a significant sale by Director Christian O. Henry. Analysts currently rate WAVE Life Sciences as a "Moderate Buy" with an average price target of $31.67, despite the company reporting negative earnings.
WAVE Life Sciences Ltd. $WVE Shares Sold by Emerald Advisers LLC
Emerald Advisers LLC reduced its stake in WAVE Life Sciences Ltd. (NASDAQ:WVE) by 8.0% in the third quarter, selling 260,219 shares. This comes amidst significant insider selling from CFO Kyle Moran and Chris Francis, who together sold over 650,000 shares in December. Despite this, institutional investors collectively own 89.73% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $31.67.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Moderate Buy" by Analysts
WAVE Life Sciences Ltd. (NASDAQ:WVE) has received a "Moderate Buy" rating from analysts, with an average 1-year price target of $31.67. Insider transactions show CFO Kyle Moran sold shares while GSK purchased a significant number of shares. Despite missing quarterly EPS expectations and having a negative net margin, the company's stock trades around $13.94 with a market capitalization of $2.33 billion.
Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Leader with 133.86% Potential Upside
Wave Life Sciences Ltd. (WVE), a biotechnology company specializing in RNA medicine, shows a potential upside of 133.86% according to analyst consensus that includes 15 buy ratings. Despite a negative forward P/E ratio and challenging financial metrics typical of early-stage biotech, the company's PRISM platform, robust pipeline, and strategic collaborations with GlaxoSmithKline and Takeda position it for future growth. Investors are watching WVE as a high-risk, high-reward opportunity in the innovative biotech sector.
A Look At Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Development Update
Wave Life Sciences (WVE) has seen increased investor interest following positive early data for its WVE-007 RNA obesity candidate, which showed significant fat loss with muscle preservation. Despite a strong 80.15% return over 90 days, the company's valuation against an average analyst target suggests it may be undervalued. While a detailed narrative estimates a fair value of US$31.93, another perspective notes its high P/S ratio compared to industry averages, indicating potential overvaluation if future trial readouts and revenue don't sustain the premium.
Wave Life Sciences (WVE) Deepens Obesity Bet With WVE-007 Focus – Is Its Platform Strategy Evolving?
Wave Life Sciences is intensifying its focus on obesity candidate WVE-007, planning a Phase 2a multidose trial and add-on incretin studies, which are key to its near-term catalyst strategy. The company presented this and other pipeline advancements at the J.P. Morgan Healthcare Conference, aiming to secure partnerships and non-dilutive capital to mitigate funding concerns amidst ongoing losses and significant R&D expenses. Investors are advised to consider the high R&D spend and potential need for further financing if clinical milestones or deals are delayed.
WAVE Life Sciences (NASDAQ:WVE) Shares Up 6.8% - Time to Buy?
WAVE Life Sciences (NASDAQ:WVE) shares rose 6.8% on Wednesday, closing at $15.1890, despite a lower trading volume. Several brokerages recently upgraded the stock and increased price targets, resulting in an average target of $31.67 and a "Moderate Buy" rating. However, the company reported a Q3 loss, missed revenue estimates, and has negative profitability metrics, alongside conflicting insider transactions where the CFO sold shares while a major shareholder purchased a significant amount.
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 for Obesity and Rapidly Advancing RNA Editing Portfolio
Wave Life Sciences announced its strategic priorities for 2026 at the J.P. Morgan Healthcare Conference, focusing on accelerating the development of WVE-007 for obesity and advancing its RNA editing portfolio. The company plans to initiate Phase 2a trials for WVE-007 and new trials for its use as an add-on or post-incretin maintenance. Wave also highlights the clinical translation of WVE-006 for AATD and the upcoming CTA filing for WVE-008 to address liver disease, emphasizing its strong financial position with a cash runway into Q3 2028.
Wave Life Sciences to expand obesity drug trials in 2026
Wave Life Sciences (NASDAQ:WVE) is set to expand its obesity treatment program in 2026, initiating multiple clinical trials for its drug WVE-007, including a Phase 2a study and evaluations as an add-on and maintenance therapy. This expansion follows promising 2025 data showing WVE-007's fat loss comparable to GLP-1 treatments while preserving muscle mass, potentially requiring only once or twice yearly dosing. Despite a recent stock decline, the company boasts strong cash reserves and positive analyst price target revisions, although it currently operates at a loss.
An experimental RNA obesity treatment could allow once‑yearly dosing
Wave Life Sciences has announced its strategic priorities for 2026, focusing on accelerating the development of WVE-007, an investigational RNA treatment for obesity. Initial single-dose data for WVE-007 showed fat loss similar to GLP-1 with muscle preservation and potential for once or twice-yearly dosing. The company also plans to advance its RNA editing portfolio, including WVE-006 for AATD and WVE-008 for liver disease, and reported a strong cash position of approximately $602 million, providing a runway into Q3 2028.
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
Wave Life Sciences has outlined its strategic priorities for 2026, focusing on accelerating the development of WVE-007 for obesity and advancing its RNA editing portfolio. The company plans to initiate a Phase 2a multidose trial for WVE-007 in individuals with obesity and comorbidities in early 2026, building on promising 2025 data showing fat loss similar to GLP-1. Wave is also expanding its RNA editing leadership with WVE-006 and aims to file a CTA for WVE-008 for liver disease in 2026, while remaining well-capitalized with a cash runway into Q3 2028.
Wave Life Sciences Highlights Strategic Priorities for 2026
Wave Life Sciences has outlined its strategic priorities for 2026, focusing on accelerating the development of WVE-007 for obesity and advancing its RNA editing portfolio. The company plans to initiate a Phase 2a multidose clinical trial for WVE-007 and further develop WVE-008 for liver disease, while also exploring a new bifunctional modality combining RNAi and RNA editing. Wave Life Sciences reports a strong financial position with cash and cash equivalents of approximately $602 million as of December 31, 2025, providing a cash runway into Q3 2028.
Wave Life Sciences Announces Plans for Phase 2a Trial of WVE-007 for Obesity and Advances RNA Editing Portfolio in 2026
Wave Life Sciences plans to initiate a Phase 2a trial for WVE-007, an investigational RNA medicine for obesity, in the first half of 2026, building on promising earlier data showing significant fat loss with muscle preservation and potential for less frequent dosing. The company also aims to advance its RNA editing programs, WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for liver disease, with further data updates and CTA filing expected in 2026. Wave is financially robust with $602 million in cash, providing a runway into Q3 2028, and will present these developments at the J.P. Morgan Healthcare Conference.
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next
Wave Life Sciences' stock fell 6.7% ahead of the J.P. Morgan Healthcare Conference, where CEO Paul Bolno will speak. Investors are keenly awaiting updates on the company's obesity program, particularly the WVE-007 gene-silencing drug, as the company previously released promising Phase 1 results and plans to issue further follow-up data in Q1 2026. The conference is also expected to spark dealmaking activities in the healthcare sector, though Wave faces risks given the early stage of its obesity trials and prior capital-raising efforts.
Wave Life Sciences Ltd. (NASDAQ:WVE) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Wave Life Sciences Ltd. (NASDAQ:WVE) has seen a 30% share price drop recently, yet its price-to-sales (P/S) ratio of 24.8x remains significantly higher than the industry average for Pharmaceuticals. Despite strong past revenue growth of 104% last year, future revenue growth is forecast at 14% per year, which is lower than the industry's predicted 31% growth. This discrepancy suggests that the current high P/S might not be justified by its growth outlook, potentially leading to future investor disappointment if the P/S ratio adjusts to reflect its growth prospects more accurately.
Wave Life Sciences (WVE) Valuation In Focus As Obesity Data, Equity Raise And Conference Updates Draw Attention
Wave Life Sciences (WVE) is drawing investor attention due to upcoming Phase 1 follow-up data for its obesity candidate WVE-007, a recent equity raise, and an appearance at the J.P. Morgan Healthcare Conference. Despite a short-term share price decline, the stock has shown significant momentum over the past 90 days. Analysts currently target a much higher price, suggesting WVE might be undervalued, though its high Price-to-Sales ratio indicates a risk if future expectations aren't met.
Wave Life Sciences (WVE) Valuation In Focus As Obesity Data, Equity Raise And Conference Updates Draw Attention
Wave Life Sciences (WVE) is drawing investor attention due to upcoming Phase 1 obesity data, a recent equity raise, and an appearance at the J.P. Morgan Healthcare Conference. Despite a short-term dip, the stock has seen significant long-term growth, and analysts currently view it as undervalued with a price target of $31.93, though its high Price-to-Sales ratio suggests potential valuation risk. The company's future hinges on successful clinical data readouts for its obesity and AATD pipelines.
Raymond James raises WAVE Life Sciences stock price target to $26
Raymond James has raised its price target for WAVE Life Sciences (NASDAQ:WVE) to $26.00 from $21.00, maintaining an Outperform rating. This increase follows positive clinical data from a competitor, validating WAVE's INHBE program, WVE-007, which is expected to be a key valuation driver despite being high-risk and in early development. Other analysts from Oppenheimer, Truist Securities, Wedbush, Jefferies, and Clear Street have also issued positive updates and increased price targets for WAVE Life Sciences due to promising advancements in its obesity treatment efforts.
